Visualization and targeting of LGR5 + human colon cancer stem cells

Nature

Volumn 545, Issue 7653, 2017, Pages 187-192

  Shimokawa, Mariko ^a   Ohta, Yuki ^a   Nishikori, Shingo ^a,b   Matano, Mami ^a   Takano, Ai ^a   Fujii, Masayuki ^a   Date, Shoichi ^a,b   Sugimoto, Shinya ^a   Kanai, Takanori ^a   Sato, Toshiro ^a  

^a KEIO UNIVERSITY   (Japan)

^b OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CASPASE 9; CETUXIMAB; KRT20 PROTEIN; LGR5 PROTEIN; OXALIPLATIN; PROTEIN; TAMOXIFEN; UNCLASSIFIED DRUG; CYTOKERATIN 20; G PROTEIN COUPLED RECEPTOR; KRT20 PROTEIN, HUMAN; LGR5 PROTEIN, HUMAN;

CANCER; CELLS AND CELL COMPONENTS; CHEMOTHERAPY; EXPERIMENTAL STUDY; GENETIC ANALYSIS; INDUCED RESPONSE; SUBPOPULATION; TUMOR; VISUALIZATION;

ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER REGRESSION; CANCER SIZE; CANCER STEM CELL; CELL DIFFERENTIATION; CELL LINEAGE; CELL PLASTICITY; CELL PROLIFERATION; COLONY FORMATION; COLORECTAL CANCER; CONTROLLED STUDY; CYTOPLASM; FIBROBLAST; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; LIVER METASTASIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STEM CELL SELF-RENEWAL; TUMOR VOLUME; UPREGULATION; ANIMAL; CELL SELF-RENEWAL; CELL TRACKING; COLONIC NEOPLASMS; DRUG EFFECTS; DRUG SCREENING; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; TRANSPLANTATION;

ANIMALS; CELL DIFFERENTIATION; CELL LINEAGE; CELL PROLIFERATION; CELL SELF RENEWAL; CELL TRACKING; COLONIC NEOPLASMS; GENE KNOCK-IN TECHNIQUES; HUMANS; KERATIN-20; MALE; MICE; MOLECULAR TARGETED THERAPY; NEOPLASTIC STEM CELLS; ORGANOIDS; RECEPTORS, G-PROTEIN-COUPLED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85019245514     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature22081     Document Type: Article

References (42)

1. Kreso, A. & Dick, J. E. Evolution of the cancer stem cell model. Cell Stem Cell 14, 275-291 (2014).
2. Nassar, D. & Blanpain, C. Cancer stem cells: basic concepts and therapeutic implications. Annu. Rev. Pathol. 11, 47-76 (2016).
3. Lapidot, T. et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367, 645-648 (1994).
4. Nguyen, L. V., Vanner, R., Dirks, P. & Eaves, C. J. Cancer stem cells: an evolving concept. Nat. Rev. Cancer 12, 133-143 (2012).
5. Zeuner, A., Todaro, M., Stassi, G. & De Maria, R. Colorectal cancer stem cells: from the crypt to the clinic. Cell Stem Cell 15, 692-705 (2014).
6. Plaks, V., Kong, N. & Werb, Z. The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells? Cell Stem Cell 16, 225-238 (2015).
7. Ricci-Vitiani, L. et al. Identifcation and expansion of human colon-cancer-initiating cells. Nature 445, 111-115 (2007).
8. O'Brien, C. A., Pollett, A., Gallinger, S. & Dick, J. E. A human colon cancer cell capable of initiating tumour growth in immunodefcient mice. Nature 445, 106-110 (2007).
9. Kobayashi, S. et al. LGR5-positive colon cancer stem cells interconvert with drug-resistant LGR5-negative cells and are capable of tumor reconstitution. Stem Cells 30, 2631-2644 (2012).
10. Kemper, K. et al. Monoclonal antibodies against Lgr5 identify human colorectal cancer stem cells. Stem Cells 30, 2378-2386 (2012).
11. Sato, T. et al. Paneth cells constitute the niche for Lgr5 stem cells in intestinal crypts. Nature 469, 415-418 (2011).
12. Barker, N. & Clevers, H. Tracking down the stem cells of the intestine: strategies to identify adult stem cells. Gastroenterology 133, 1755-1760 (2007).
13. Driessens, G., Beck, B., Caauwe, A., Simons, B. D. & Blanpain, C. Defning the mode of tumour growth by clonal analysis. Nature 488, 527-530 (2012).
14. + stem cell activity in mouse intestinal adenomas. Science 337, 730-735 (2012).
15. - cells are radioresistant cancer-initiating stem cells in the colon and intestine. Cell Stem Cell 16, 627-638 (2015).
16. Fujii, M. et al. A colorectal tumor organoid library demonstrates progressive loss of niche factor requirements during tumorigenesis. Cell Stem Cell 18, 827-838 (2016).
17. Merlos-Suárez, A. et al. The intestinal stem cell signature identifes colorectal cancer stem cells and predicts disease relapse. Cell Stem Cell 8, 511-524 (2011).
18. Dalerba, P. et al. Single-cell dissection of transcriptional heterogeneity in human colon tumors. Nat. Biotechnol. 29, 1120-1127 (2011).
19. + cells with an antibody-drug conjugate for the treatment of colon cancer. Sci. Transl. Med. 7, 314ra186 (2015).
20. Vermeulen, L. et al. Wnt activity defnes colon cancer stem cells and is regulated by the microenvironment. Nat. Cell Biol. 12, 468-476 (2010).
21. Cernat, L. et al. Colorectal cancers mimic structural organization of normal colonic crypts. PLoS One 9, e104284 (2014).
22. Snippert, H. J. et al. Intestinal crypt homeostasis results from neutral competition between symmetrically dividing Lgr5 stem cells. Cell 143, 134-144 (2010).
23. Kemper, K., Rodermond, H., Colak, S., Grandela, C. & Medema, J. P. Targeting colorectal cancer stem cells with inducible caspase-9. Apoptosis 17, 528-537 (2012).
24. + secretory progenitor cells revert to stem cells upon crypt damage. Nat. Cell Biol. 14, 1099-1104 (2012).
25. + stem cells are indispensable for radiation-induced intestinal regeneration. Cell Stem Cell 14, 149-159 (2014).
26. Tetteh, P. W. et al. Replacement of lost Lgr5-positive stem cells through plasticity of their enterocyte-lineage daughters. Cell Stem Cell 18, 203-213 (2016).
27. Buczacki, S. J. et al. Intestinal label-retaining cells are secretory precursors expressing Lgr5. Nature 495, 65-69 (2013).
28. Tian, H. et al. A reserve stem cell population in small intestine renders Lgr5-positive cells dispensable. Nature 478, 255-259 (2011).
29. Basak, O. et al. Induced quiescence of Lgr5+ stem cells in intestinal organoids enables diferentiation of hormone-producing enteroendocrine cells. Cell Stem Cell 20, 177-190.e4 (2017).
30. Chafer, C. L. et al. Poised chromatin at the ZEB1 promoter enables breast cancer cell plasticity and enhances tumorigenicity. Cell 154, 61-74 (2013).
31. Brooks, M. D., Burness, M. L. & Wicha, M. S. Therapeutic Implications of cellular heterogeneity and plasticity in breast cancer. Cell Stem Cell 17, 260-271 (2015).
32. Gupta, P. B. et al. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell 146, 633-644 (2011).
33. Todaro, M., Perez Alea, M., Scopelliti, A., Medema, J. P. & Stassi, G. IL-4-mediated drug resistance in colon cancer stem cells. Cell Cycle 7, 309-313 (2008).
34. Kaiser, J. The cancer stem cell gamble. Science 347, 226-229 (2015).
35. Takebe, N. et al. Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update. Nat. Rev. Clin. Oncol. 12, 445-464 (2015).
36. Ran, F. A. et al. Genome engineering using the CRISPR-Cas9 system. Nat. Protocols 8, 2281-2308 (2013).
37. Fujii, M., Matano, M., Nanki, K. & Sato, T. Efcient genetic engineering of human intestinal organoids using electroporation. Nat. Protocols 10, 1474-1485 (2015).
38. Muñoz, J. et al. The Lgr5 intestinal stem cell signature: robust expression of proposed quiescent '+ 4' cell markers. EMBO J. 31, 3079-3091 (2012).
39. null mouse: an excellent recipient mouse model for engraftment of human cells. Blood 100, 3175-3182 (2002).
40. Matano, M. et al. Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids. Nat. Med. 21, 256-262 (2015).
41. Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. Nat. Methods 9, 676-682 (2012).
42. Bolte, S. & Cordelières, F. P. A guided tour into subcellular colocalization analysis in light microscopy. J. Microsc. 224, 213-232 (2006).